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Summary
Malignant hyperthermia (MH) is a pharmacogenetic dis-
order of skeletal muscle that is triggered in genetically
predisposed individuals by common anesthetics and
muscle relaxants. The ryanodine receptor (RYR1) is mu-
tated in a number of MH pedigrees, some members of
which also have central core disease (CCD), an inherited
myopathy closely associated withMH.Mutation screen-
ing of 6 kb of the RYR1 gene has identified four adjacent
novel mutations, C6487T, G6488A, G6502A, and
C6617T, which result in the amino acid alterations
Arg2163Cys, Arg2163His, Val2168Met, and
Thr2206Met, respectively. Collectively, these mutations
account for 11% of MH cases and identify the gene
segment 6400–6700 as a mutation hot spot. Correlation
analysis of the in vitro contracture-test data available
for pedigrees bearing these and other RYR1 mutations
showed an exceptionally good correlation between caf-
feine threshold and tension values, whereas no corre-
lation was observed between halothane threshold and
tension values. This finding has important ramifications
for assignment of the MH-susceptible phenotype, in ge-
notyping studies, and indicates that assessment of re-
combinant individuals on the basis of caffeine response
is justified, whereas assessment on the basis of halothane
response may be problematic. Interestingly, the data sug-
gest a link between the caffeine threshold and tension
values and the MH/CCD phenotype.
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Introduction
Malignant hyperthermia (MH) is a potentially fatal dis-
order of skeletal muscle. An MH episode can be precip-
itated in susceptible individuals by exposure to triggering
agents, such as inhalational anesthetics or depolarizing
muscle relaxants. The clinical features of anMH episode
are hyperthermia, accelerated muscle metabolism, con-
tractures, metabolic acidosis, and tachycardia. In the ab-
sence of triggering agents, susceptible individuals are
normal, although cramps, fatigue, and heat intolerance
have been reported (Denborough et al. 1962; Ellis and
Heffron 1985; Gronert 1986).
Because of the subclinical nature of the condition, di-
agnosis in advance of exposure to anesthesia is difficult.
However, an in vitro diagnostic test for diagnosis of
susceptibility to MH has been developed and is based
on the differential contractile response of normal and
MH muscle to caffeine (Kalow et al. 1970) and to hal-
othane (Ellis and Harriman 1973). A standardized Euro-
pean in vitro contracture test (IVCT) was established in
1984 (EuropeanMalignant Hyperthermia Group 1984).
It allows the following diagnoses to be made: MH sus-
ceptible (MHS), MH equivocal (MHE), andMH normal
(MHN). If a muscle-biopsy strip produces a sustained
increase in muscle tension of 0.2 g, at X2% halothane
and, independently, at a caffeine concentration of X2
mM, the patient is considered to be MHS. MHN is di-
agnosed if the 0.2-g threshold is not attained at these
concentrations, whereas MHE is diagnosed if the thresh-
old tension is attained with caffeine (MHE[c]) or hal-
othane (MHE[h]) but not with both. The clinical and
biochemical relationship between the MHS and MHE
phenotypes is unclear.
Molecular-genetic studies of humans and pigs have
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Table 1
RYR1 Mutations Identified in MHS and CCD Families
Mutation Reference Nucleotide Sequence Amino Acid Sequencea
MH Families
with Mutation
Cys35Arg Lynch et al. (1997) aagctc t/c gcctggcc eqlKl C/R LaaEG 1 family
Arg163Cysb Quane et al. (1993) aaggtc c/t gcgttggg EGEKV R/C VGDDI 2%
Gly248Arg Gillard et al. (1992) tatgag g/a ggggagct lvyYE g/r Gavctc 2%
Gly341Arg Quane et al. (1994b) aagtac g/a gggagtca peIKY G/R ESlcf 6%
Ile403Metb Quane et al. (1993) cgcatgat c/g cacagc QAARm I/M hsTng 1 family
Tyr522Serb Quane et al. (1994a) cttctct a/c tgaactc Ivnll Y/S elLAS 1 family
Arg552Trp Keating et al. (1997) ctggat c/t ggctggag vsKLd r/w leaSSd 1 family
Arg614Cys Gillard et al. (1991) gctgta c/t gctccaac NGVAV R/C SnQdl 4%
Arg614Leu Quane et al. (1997) gctgta c/a gctccaa NGVAV R/L SnQdl 2%
Arg2163Cys This study cagatc c/t gctcgctg cLgQI R/C SLLiV 4%
Arg2163Hisb This study cagatcc g/a ctcgctg cLgQI R/H SLLiV 1 family
Val2168Met This study ctcatc g/a tgcagatg RSLLi V/M QMgpQ 7%
Thr2206Met This study cacgaga c/t ggtcatg LgMHE T/M VMeVM 1 family
Gly2435Arg Keating et al. (1994);
Phillips et al.
(1994)
ctgctc g/a gacgctgt LIDLL G/R RCAPE 4%
Arg2436Hisb Zhang et al. (1993) ctcggac g/a ctgtgca IDLLG R/H CAPEm 1 family
Arg2458Cys Manning et al.
(1998)published
data
atcctc c/t gctccctt iRAiL R/C SLVPl 4%
Arg2458His Manning et al.
(1998)published
data
atcctcc g/a ctccctt iRAiL R/H SLVPl 4%
a Conserved/semiconserved amino acids are indicated by capital letters.
b Associated with CCD.
c G248 conserved in seven of nine RYR genes.
d R552 conserved in eight of nine RYR genes.
established the ryanodine receptor (RYR1) on chro-
mosome 19 as the primary MHS locus (MHS1; MIM
180901) (MacLennan et al. 1990; McCarthy et al.
1990). The RYR1 protein has a subunit size of 560 kD
and forms an elaborate tetrameric structure that acts
both as a calcium-release channel and a foot structure
bridging the gap between the sarcoplasmic reticulumand
the t-tubule, in skeletal muscle (reviewed in MacLennan
and Phillips 1992). The RYR1 gene is comprised of 106
exons encompassing a total of 160 kb and, as such, is
one of the most complex genes characterized, to date
(Phillips et al. 1996).
Genetic heterogeneity has been reported in MH. Al-
ternative MHS loci have been proposed to reside on
chromosomes 17q11.2-q24 (Levitt et al. 1992) and
7q11.23-q21.1 (Iles et al. 1994), LOD scores in favor
of linkage in these cases are marginal. In addition, in a
single large pedigree, linkage has been established be-
tween the MHS locus and markers on the q13.1 region
of chromosome 3 (Sudbrak et al. 1995). More recently,
in a second single large pedigree, linkage has been es-
tablished between the MHS locus and markers on chro-
mosome 1q (Robinson et al. 1997), and putative caus-
ative mutations have been identified in amajor candidate
gene in this region, CACNL1A3, which encodes the a1-
subunit of the dihydropyridine receptor (Monnier et al.
1997).
Mutation screening of the RYR1 gene in MHS indi-
viduals has identified 13 mutations, to date. The details
of these mutations and their incidence are shown in table
1. Mutations in the RYR1 gene also have been described
in central core disease (CCD), a rare inherited myopathy
(Shy and Magee in 1956) that is closely associated with
MH (Shuaib et al. 1987). Patients with CCD often ex-
hibit hypotonia and proximal muscle weakness in in-
fancy, leading to delayed motor milestones. CCD is a
disorder that exhibits substantial variability both clini-
cally and histologically, and the severity of symptoms
may vary from normal to severe. Diagnosis of CCD is
by histological examination of muscle-biopsy tissue,
which shows amorphous central areas (cores) in type 1
fibers, with a relative lack, if not a complete absence, of
mitochondria in core regions (Hayashi et al. 1989). Pa-
tients with CCD are at risk for MH and, in almost all
cases, are diagnosed as MHS by the IVCT.
Autosomal dominant inheritance of theMHS trait has
generally been observed in most large European MHS
families, although it is unclear whether this will be the
case for all MHS families. However, it is not clear what
percentage of individuals diagnosed as MHS will actu-
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ally develop a clinical episode of MH when exposed to
a triggering agent. One report, by Kalow (1987), based
on an epidemiological study of MH “at-risk” individ-
uals, estimated that approximately one-third of suscep-
tible individuals develop a clinical episode of MH when
exposed to a triggering agent, indicating a penetrance
of .33.
The thirteen RYR1 mutations identified, to date, are
located in two regions of the RYR1 gene, the amino-
terminal and central regions, and indicate that other mu-
tations causing MH and CCDmay cluster in these areas.
We have analyzed 6 kb covering these regions of the
RYR1 gene, and, in this article, we report four novel
mutations in the central portion of the gene. IVCT data
for RYR1 mutations described elsewhere and for the
mutations reported in this article were collected and have
allowed us to perform the first major genotype-pheno-
type correlation for RYR1 mutations and IVCT
responses.
Patients and Methods
Patients
The pedigrees of the families we investigated are
shown in figure 1. At age 12 years, the proband in ped-
igree D1 exhibited symptoms consistent with the onset
of an MH crisis, while undergoing opthalmic surgery
for the first time. Ten minutes after initiation of anes-
thesia with halothane and succinylcholine, body tem-
perature rose to 37.4C, accompanied by myoglobinu-
rea, masseter spasm, and ventricular arrythmia. The
patient’s maximal heart rate was measured at 178 beats
per min (bpm), his maximal potassium level was 4.8
mEq/liter, and his maximal creatine kinase (CK) level
was 6,0520 U/liter. Dantrolene therapy was not under-
taken to reverse the course of the crisis, and the patient
survived without sequela. The proband in pedigree D2
had an MH crisis at age 27 years, while undergoing
surgery (orthopedic) for the first time, with halothane
and succinylcholine. The maximal temperature recorded
during the MH crisis was 39.2C. The anesthesia du-
ration prior to development of the MH crisis was 90
min. Other characteristics of this crisis includedmasseter
spasm, inappropriate tachypnea, and sinus tachycardia.
The maximal heart rate was measured at 150 bpm, and
the maximal CK level was 12,500 U/liter. Dantrolene
therapy was not undertaken.
The S6 pedigree is of Swiss descent. A detailed de-
scription of the proband in this pedigree has been pub-
lished previously by Urwyler et al. (1994).
The proband in the Irish pedigree, Ir4, experienced an
MH crisis while undergoing orthopedic surgery. After
initiation of anesthesia with isoflurane and succinylcho-
line, masseter spasm developed. Clinical symptoms in-
cluded myoglobinurea and cola-colored urine during the
perioperative period. The maximal CK level was mea-
sured at 40,700 U/liter. Rapid reversal of the crisis was
achieved without dantrolene intervention, and the pro-
band survived without sequela.
The proband in the Italian pedigree, It2, had under-
gone eight previous surgical procedures, under general
anesthesia, before presenting with a fulminant MH cri-
sis. On six of these previous occasions, anMH-triggering
anesthetic had been used. Histological examination of
the muscle revealed a predominance of type I fibers, with
central cores present in many fibers, indicating the pres-
ence of asymptomatic CCD. A complete clinical picture
of this case is documented in the study by Tegazzin et
al. (1994).
All IVCTs were performed according to the standard-
ized protocol. In this protocol, muscle strips are stan-
dardized to a 15–25-mm length and a 100-mg weight.
The appropriate informed consent was obtained from
all subjects.
RYR1 Mutation Analysis
Genomic DNA was isolated from whole blood lysate
with a phenol/chloroform extraction followed by iso-
propanal precipitation. Total RNA was isolated from
frozen MHS muscle-biopsy samples, by acid guanidi-
nium-phenol-chloroform extraction (Chomczynski and
Sacchi 1987). First-strand cDNA was synthesized by use
of the Promega reverse-transcription system and random
primers. PCR amplification of overlapping RYR1 frag-
ments of 250–400 bp in length was performed by use
of primer sets designed from the published human RYR1
sequence (Zorzato et al. 1990).
The primer sets chosen covered the gene sections10
to 3088 and 5114 to 8052. The PCR reactions for SSCP
analysis were performed as outlined elsewhere (Quane
et al. 1993). Nondenaturing gel electrophoresis for SSCP
detection was undertaken by use of the following three
conditions: 6% polyacrylamide:bisacrylamide (99:1)
with 5% glycerol, at room temperature and at 4C, and
without glycerol, at 4C (Orita et al. 1989).
The four mutations described were detected in the
RYR1 fragment 6379–6766. This fragment was ampli-
fied by use of the primers 6379F (5′-CAG TAC GAC
GGG CTG GGT GAG-3′) and 6766R (5′-GCC ACT
GTT CTC CAG CAG GTA-3′). Direct sequencing was
performed as described by Quane et al. (1993), by use
of primer 6379F.
A 64-bp product of exon 39, encompassing the mu-
tations C6486T, G6487A, and G6501A, was amplified
from genomic DNA by use of primers 6464F (5′-TGC
TCG AGT GCC TCG GCC AGAT-3′) and 6506R (5′-
TTC TCC TCC TGG GGG CCC ATCT-3′). The mu-
tation C6617T is located in exon 40 of the RYR1 gene,
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Figure 1 Segregation of the RYR1 mutations Arg2163Cys (in pedigrees D1 and D2), Arg2163His (in pedigree It2), Val2168Met (in
pedigree S6), and Thr2206Met (in pedigree Ir4). Blackened symbols indicate individuals who are MHS; unblackened symbols indicate individuals
who are MHN; half-blackened symbols indicate individuals who are MHE(h); and a question mark (?) indicates individuals for whom disease
status is unknown. Segregation of the respective mutations also is indicated: a plus sign () indicates that an individual is heterozygous for the
mutant allele, and a minus sign () indicates that an individual is homozygous for the normal allele.
and a 74-bp product encompassing this mutation was
amplified by use of primers 6588F (5′-CCT GAT GAG
GGC GCT GGG CAT-3′) and 6641R (5′-TGG ACT
CGC CGC CCC CGA GGA-3′). Standard PCR condi-
tions were used for amplification (denaturation at 94C
for 1 min, annealing at 64C for 1 min [both primer
sets], and extension at 72C for 1 min).
Because of the close proximity of the three adjacent
mutations in exon 39 and the unavailability of a restric-
tion site for the C6617T mutation in exon 40, SSCP
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analysis was the method of choice for detection of these
mutations. The optimal electrophoretic conditions for
detection of these mutations were 10% polyacryla-
mide:bisacrylamide (99:1) with 5% glycerol, at 4C and
50 W.
Statistical Analysis
IVCT data were collected for all published RYR1 mu-
tations, with the exception of Arg2435His and
Gly248Arg, which are rare in the European MHS pop-
ulation. The IVCT results were recorded as four separate
entities—namely, the concentrations of caffeine and hal-
othane at which a threshold tension of 0.2 g is reached
and the tensions generated by 2% (0.44 mM) halothane
and 2 mM caffeine. All data analysis was undertaken
by use of the Minitab statistical package (Ryan et al.
1985). Comparison of mean values of caffeine threshold
concentration versus halothane threshold concentration
and of the tensions generated at 2 mM caffeine versus
2% halothane, for the different mutations, was under-
taken by use of a two-sample t-test. Variation in the
IVCT response was determined by use of one-way anal-
ysis of variants. Pairwise comparison of IVCT data for
each mutation was performed by use of a Tukey pair-
wise-comparison test ( ). Direct comparison of theP 1 .05
IVCT response for individuals carrying mutations
Arg614Cys and Arg614Leu was completed by use of the
student’s two-sample t-test.
Results
RYR1 Mutation Analysis
Screening for novel mutations in the regions 10 to
3088 and 5114 to 8052 was undertaken by use of the
SSCP technique (Orita et al. 1989). The previously pub-
lished RYR1 mutations (table 1) were not detected in
these samples. The majority of aberrant SSCP patterns
detected in these regions were due to commonly occur-
ring polymorphisms (Gillard et al. 1992), since several
MHS individuals were homozygous for either allele, and/
or the SSCP pattern was present in normal controls.
Four unique SSCP patterns were detected in MHS in-
dividuals from families D1, D2, It2, S6, and Ir4, in the
fragment 6379–6766. Direct sequencing of this ampli-
fied fragment identified the presence of four mutations:
C6487T in the individuals from families D1 and D2,
G6488A in the individual from family It2, G6502A in
the individual from family S6, and C6617T in the in-
dividual from family Ir4. These mutations result in the
amino acid alterations Arg2163Cys, Arg2163His,
Val2168Met, and Thr2206Met, respectively. The
C6617T mutation also was detected independently in
pedigree Ir4, by use of a novel mutation–scanning
method (authors’ unpublished data). Full details show-
ing the DNA and amino acid sequences flanking these
mutations and those reported elsewhere are shown in
table 1.
In order to analyze these mutations in genomic DNA,
it was necessary to design two primer sets for amplifi-
cation of the mutations, since C6487T, G6488A, and
G6502A are located in exon 39 whereas the fourth mu-
tation, C6617T, occurs in exon 40. When these primer
sets were designed, the intron/exon boundaries of the
human RYR1 gene were not available, and primers were
selected on the basis of trial and error. Primer pairs
6464F and 6506R were used successfully to amplify a
64-bp region encompassing the three mutations in exon
39, and primer pairs 6588F and 6641R were used to
amplify the 74-bp region encompassing the C6617Tmu-
tation in exon 40.
SSCP analysis was employed and allowed differential
detection of each mutation. By use of SSCP analysis,
these candidate mutations were shown to be absent in
200 normal chromosomes analyzed (data not shown).
Of 70 available MHS cDNA samples, the Arg2163His
mutation was detected in one Belgian MHS individual
(10B), in addition to the index case. The Val2168Met
mutation was identified in an additional three Swiss sam-
ples and in one German sample, indicating that this mu-
tation may be one of the most common MHS mutations
in the European population or that there may be a foun-
der effect in the Swiss/German population. The
Thr2206Met mutation was detected in a German MHS
individual. These additional, apparently unrelated, in-
dividuals bearing the Val2168Met mutation and the
Thr2206Met mutation were the only members of their
families tested for susceptibility to MH, by use of the
IVCT. Thus, it was not possible to perform haplotype
analysis to establish whether the relatively common
Val2168Met mutation arose through a founder effect.
Segregation Analysis of the Novel Mutations
Segregation analysis of the mutations Arg2163Cys,
Arg2163His, Val2168Met, and Thr2206Met was per-
formed in pedigrees D1 and D2, It2, S6, and Ir4, re-
spectively (fig. 1). The candidate mutations segregated
with the MHS phenotype, in all cases. Individual IV:15
of pedigree S6 was diagnosed as MHE(h) (fig. 1). The
Val2168Met mutation was absent in this individual.
The IVCT data of the individuals from the five ped-
igrees in figure 1 are shown in table 2. The IVCT results
are presented under four headings—namely, the concen-
trations of caffeine and halothane required to generate
a threshold tension of 0.2 g in each muscle strip and the
tension generated in each muscle strip at 2 mM caffeine
and at 2% (0.44 mM) halothane.
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Table 2
IVCT Data for MHS and MHE Members of MH Pedigrees Bearing the Novel RYR1 Mutations
Arg2163Cys (Pedigrees D1 and D2), Arg2163His (Pedigree It2), Val2168Met (Pedigree S6), and
Thr2206Met (Pedigree Ir4)
FAMILY AND
INDIVIDUAL
TENSION
THRESHOLD
CONCENTRATION
IVCT
STATUS
RYR1
MUTATIONd
At 2 mM
Caffeine
(g)
At 2% [.44 mM]
Halothane
(g)
Caffeine
(mM)
Halothanea
(%)
D1:
II:2 1.2 1.05 .5 .5 MHS 
II:4 1.4 1.3 .5 1.0 MHS 
II:6 1.1 3.9 1.5 .5 MHS 
II:8 1.05 2.7 1.0 .5 MHS 
III:1 .5 1.2 1.0 .5 MHS 
III:3 .9 1.4 1.5 2.0 MHS 
III:4 1.5 2.9 .5 .5 MHS 
III:5 .9 2.5 1.0 .5 MHS 
III:6 .9 1.0 1.0 .5 MHS 
III:10 1.2 1.85 1.0 .5 MHS 
III:11 1.9 2.6 1.0 .5 MHS 
D2:
II:2b 2.3 1.3 !4 .5 MHS 
II:5 .9 1.1 1.0 1.0 MHS 
III:1b 3.6 2.6 !4 .5 MHS 
III:3b 3.8 1.1 !4 1.0 MHS 
III:6 1.3 2.2 .5 .5 MHS 
IV:1 1.4 2.7 1.0 .5 MHS 
IV:2 .2 1.05 2.0 .5 MHS 
IV:3 .5 .65 1.5 .5 MHS 
It2:
II:2 1.88 6.94 1.5 .5 MHS 
III:1 1.48 .74 .5 1.0 MHS 
S6:
III:2 .5 2.3 2.0 .5 MHS 
III:3 .2 1.0 2.0 1.0 MHS 
III:4 .5 2.8 1.5 .5 MHS 
III:6 .9 .6 2.0 .5 MHS 
III:8 1.6 2.0 2.0 .5 MHS 
III:10 .2 1.8 2.0 .5 MHS 
III:12 .8 2.0 1.0 .5 MHS 
III:13 .9 2.8 1.5 .5 MHS 
III:15 .2 1.1 2.0 .5 MHS 
III:16c ) ) ) ) ) )
III:18 1.2 1.0 1.0 .5 MHS 
III:20 .6 .7 1.0 .5 MHS 
IV:3 .8 .5 .5 .5 MHS 
IV:4 .4 1.8 1.5 1.0 MHS 
IV:9 2.0 4.5 1.5 .5 MHS 
IV:14 .2 1.3 2.0 .5 MHS 
IV:15 .1 .6 4.0 .5 MHE(h) 
IV:16 .5 .8 2.0 1.0 MHS 
Ir4:
II:4 .35 1.4 1.5 1.0 MHS 
II:6 2.0 3.34 1.0 1.0 MHS 
II:7 .1 .3 4.0 2.0 MHE(h) 
III:1 1.4 3.25 1.0 1.0 MHS 
III:2 .35 1.67 1.5 .5 MHS 
a The data 0.5%, 1.0%, and 2.0% are equivalent to 0.11 mM, 0.22 mM, and 0.44 mM halothane,
respectively.
b Tested prior to introduction of standardized protocol in 1984.
c MH death.
d ,  indicate presence or absence of a RYR1 mutation, respectively.
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Table 3
Comparison of IVCT Mean Values of Caffeine Threshold
Concentration versus Those of Halothane Threshold Concentration,
for Different RYR1 Mutations
MUTATION (n)
THRESHOLD CONCENTRATION
(SEM)
t
P
VALUEa
Caffeine
(mM)
Halothaneb
(%)
Cys35Arg (10) 1.80 (.11) 1.35 (.22) [.3] 1.80 .095
Arg163Cys (4) .750 (.14) .625 (.25) [.14] .65 NS
Gly341Arg (17) 1.08 (.15) .85 (.14) [.19] 1.14 NS
Arg552Trp (14) 1.07 (.16) .96 (.09) [.21] .58 NS
Arg614Cys (21) 1.42 (.11) 1.00 (.12) [.22] 2.69 .01
Arg614Leu (8, 7)c .81 (.12) .50 (0) [.11] 2.33 .05
Arg2163Cys (16) 1.03 (.11) .65 (.08) [.14] 2.72 .01
Val2168Met (19) 1.58 (.10) .61 (.05) [.13] 8.56 !.001
Thr2206Met (4) 1.25 (.14) .87 (.13) [.19] 1.96 .11
Gly2435Arg (13) 1.11 (.14) .84 (.15) [.18] 1.29 NS
Arg2458Cys (6) 1.83 (.11) .66 (.08) [.14] 8.68 !.001
a NS  not significant.
b The halothane concentration in millimorgans is given in brackets.
c Caffeine and halothane data were obtained for eight and seven
samples, respectively.
Table 4
Comparison of IVCT Mean Values of Tension at 2 mM Caffeine
versus those of Tension at 2 mM Halothane, for Different RYR1
Mutations
MUTATION (n)
TENSION (SEM)
(g)
t
P
VALUEa
At 2 mM
Caffeine
At 2% [.44 mM]
Halothane
Cys35Arg (10) .35 (.05) .96 (.20) 2.93 .01
Arg163Cys (4) 2.12 (.33) 2.17 (.75) .06 NS
Gly341Arg (17) 1.96 (.37) 2.03 (.32) .14 NS
Arg552Trp (14) 1.62 (.29) 1.85 (.31) .56 NS
Arg614Cys (21) .95 (.13) 1.52 (.23) 2.16 .04
Arg614Leu (8, 7)b 1.47 (.21) 2.38 (.41) 2.12 .06
Arg2163Cys (16) 1.40 (.22) 1.84 (.20) 1.50 NS
Val2168Met (19) .70 (.11) 1.64 (.23) 3.73 !.001
Thr2206Met (4) 1.02 (.41) 2.42 (.51) 2.12 .08
Gly2435Arg (13) 1.72 (.37) 2.53 (.40) 1.50 NS
Arg2458Cys (6) .34 (.06) 1.10 (.12) 5.69 !.001
a NS  not significant.
b Caffeine and halothane data were obtained for eight and seven
samples, respectively.
Statistical Analysis of IVCT Data for Known and Novel
RYR1 Mutations
For the statistical analysis, two mutations
(Arg2163His and Arg2458His) were excluded because
the sample size (two) was too small. Also, IVCT data
greater than the threshold values for MHE individuals
bearing known RYR1 mutations were included, al-
though this actually amounted to the inclusion of IVCT
data for only three MHE(h) individuals from a pedigree
with the Arg2458Cys mutation (Manning et al. 1998).
Homozygous MHS individuals were excluded in the
analysis. For analysis of mutations reported elsewhere,
IVCT data for genotyped individuals from European
MH centers were used.
Comparison of the mean values of caffeine threshold
concentration versus those of halothane threshold con-
centration (i.e., the concentrations of caffeine and hal-
othane required to attain a threshold tension of 0.2 g in
the IVCT) for each RYR1 mutation, by use of a two-
sample t-test, is presented in table 3. The analysis shows
a significant difference between the thresholds for mu-
tations Arg614Cys, Arg614Leu, Arg2163Cys,
Val2168Met, and Arg2458Cys. The differences ob-
served for Cys35Arg and Thr2206Met approached sta-
tistical significance ( and , respectively)P  .095 P  .11
and may be biologically significant. In all cases, for the
mutations mentioned, the halothane threshold was
lower than the caffeine threshold.
Comparison of the mean values of contracture tension
generated at 2 mM caffeine versus at 2% (0.44 mM)
halothane, by use of the same test, is presented in table
4. The analysis shows a significant difference between
the tensions for mutations Cys35Arg, Arg614Cys,
Val2168Met, and Arg2458Cys. The differences ob-
served for Arg614Leu and Thr2206Met approached sta-
tistical significance ( and , respectively)P  .06 P  .08
and may be biologically significant. For all cases for
which a significant difference was observed, the tensions
recorded at 2% (0.44 mM) halothane were higher than
the tensions recorded at 2 mM caffeine.
Statistical analysis of IVCT responses for the
Arg614Cys and the Arg614Leu mutations, by use of a
two-sample t-test, showed that Arg614Leu had a sig-
nificantly lower caffeine threshold ( , )t  3.66 P  .002
and halothane threshold ( , ) thant  4.13 P  .0005
Arg614Cys. Comparison of the tension values at 2 mM
caffeine and at 2% (0.44 mM) halothane showed that
differences approached statistical significance ( ,t  2.01
and , , respectively) and indi-P  .07 t  1.96 P  .08
cated that the Arg614Leu mutation is likely to yield
higher tensions than the Arg614Cys mutation.
The caffeine threshold, halothane threshold, tension
generated at 2 mM caffeine, and tension generated at
2% (0.44 mM) halothane were compared between the
different mutations, by use of the ANOVA test and Tu-
key pairwise comparison ( ). The results of thisP 1 .05
analysis show that there is significant variation in the
four IVCT measurements for all of these mutations. Be-
cause of the variation, it was not possible to critically
assess statistical differences between the IVCT responses
associated with mutations in the N-terminal region ver-
sus those in the central region of the RYR1 gene. None-
theless, direct examination of the data suggests that mu-
tations in the central portion of the gene may be
associated with a more sensitive halothane phenotype.
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Figure 2 Correlation analysis of IVCT threshold and tension values for different RYR1 mutations in MHS individuals. A, Caffeine
threshold (in millimorgans) and tension (in grams) values ( , df 9, ) B, Halothane threshold (as percentages) and tension (inr  .91 P 1 .001
grams) values ( , df 9, no significant correlation). Mutations are denoted by their location in the RYR1 gene. Arg614Cys and Arg614Leur  .32
are denoted by 614C and 614L, respectively.
Statistical analysis of a larger data set will be necessary
to clarify this point.
Correlation analysis was performed for IVCT thresh-
old and tension values for caffeine and halothane, for
each mutation. A graphical representation of the data
from the correlation analysis is shown in figure 2A and
B. For caffeine, there was a statistically significant cor-
relation between threshold and tension values for each
mutation ( , df 9, ). For halothane, nor  .91 P 1 .001
significant correlation between threshold and tension
values was observed ( , df 9). Correlation analysisr  .32
also was performed for the IVCT threshold values of
both agents, but no significant correlation was observed
( ). However, a correlation was observed for ther  .35
IVCT tension values of both agents ( , ).r  .72 P 1 .05
Discussion
In the work reported here, we have identified four
novel mutations in the RYR1 fragment 6379–6766 in
MHS individuals. The combined incidence of these four
novel mutations amongMHS individuals may be as high
as 11%. These results (a) identify exon 39 of the RYR1
gene as a high priority exon, for mutation screening, and
(b) confirm that MHS mutations cluster in the central
region of the RYR1 gene, as well as in the amino-ter-
minal region.
These mutations satisfy the genetic criteria for caus-
ative mutations, and comparison of the ryanodine-re-
ceptor isoforms sequenced, to date, shows that the
amino acids Arg2163 and Val2168, as well as several
amino acids in their immediate vicinity, are conserved
across RYR1, RYR2, and RYR3 isoform sequences avail-
able from GenBank (accession numbers D17389,
D21070, D21071, D45899, J05200, M91451, U50465,
U97329, X15750, X95267, X98330, and Y07749) (ta-
ble 1).
The Arg2163His mutation seems to confer suscepti-
bility toMH and predisposition to CCD in an individual,
since cores were present in type I fibers in the proband
(II:2) in family It2. In addition, no other mutation was
detected in the RYR1 regions 10 to 3088 and 5114 to
8052 in this individual, indicating that, at least in the
MH/CCD regions of the RYR1 gene, a second mutation
in addition to the Arg2163His mutation is not likely to
be present in the proband (II:2). Individual III:1, the
daughter of the proband (II:2), is asymptomatic for
CCD, even though she also has the segregatingmutation.
Similar observations for other RYR1 mutations inMHS/
CCD pedigrees have been documented elsewhere (Quane
et al. 1993, 1994a; Zhang et al 1993). It is unclear why
cores develop in the muscle of some MHS individuals.
If CCD and susceptibility to MH are manifestations of
a common mechanistic defect, then presumably the ge-
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netic background of each individual may influence the
level of manifestation of the phenotype.
To examine the correlation between genotype and
phenotype, we undertook a full statistical analysis of
IVCT data generated for the RYR1 MHS mutations re-
ported here and for the mutations reported elsewhere.
We observed that the halothane threshold for 5 of 11
RYR1 mutations was significantly lower than the caf-
feine threshold (table 3). Similarly, the tensions gener-
ated at 2% (0.44 mM) halothane for 4 of 11 RYR1
mutations was significantly higher than the tensions gen-
erated at 2 mM caffeine (table 4). By contrast, we did
not observe any case in which the caffeine threshold was
significantly lower than the halothane threshold or in
which the tension generated at 2 mM caffeine was sig-
nificantly higher than the tension generated at 2% (0.44
mM) halothane. This suggests that response to halo-
thane may be a more sensitive indicator of susceptibility
to MH than response to caffeine or, alternatively, that
muscle generally may be more sensitive to halothane-
induced contracture than to caffeine-induced contrac-
ture. Interestingly, at the Cork MH center, the number
of MHE(h) diagnoses is much greater than the number
of MHE(c) diagnoses (51 vs. 4). These results suggest
that the probability of an MHE(h) individual carrying
a segregating mutation will be different than the prob-
ability of an MHE(c) individual carrying such a muta-
tion. In agreement with this notion, examination of
MHS families studied, to date, in which an RYR1 mu-
tation is segregating with the MHS phenotype shows
that the segregating mutation is present in 2 (33%) of
6 MHE(c) individuals and in 4 (22%) of 18 MHE(h)
individuals.
Correlation of the IVCT threshold values with the
tension values showed a highly significant correlation
for caffeine but not for halothane. In addition, no sig-
nificant correlation was observed between the IVCT
threshold values of both agents, whereas a significant
correlation was observed between the IVCT tension val-
ues of both agents. Indeed, considering that the IVCT
is a relatively crude bioassay and that the data points
were collected from laboratories throughout Europe,
such a good correlation reinforces the quality of the
standardized IVCT. The different responses observed for
halothane and caffeine suggest a different mechanism of
action for these agents. Several explanations could be
proposed to explain the lack of a significant correlation
between halothane threshold and tension values. Vari-
ability in halothane measurements is a realistic expla-
nation, since halothane measurements can be problem-
atic. Halothane is a volatile agent and does not dissolve
in auqeous solutions as well as caffeine does. Thus, it is
more difficult to control steady-state concentrations of
halothane. In addition, the IVCT is performed with four
concentrations of caffeine (0.5 mM, 1.0 mM, 1.5 mM,
and 2.0 mM) and three concentrations halothane (0.5%
[0.11 mM], 1% [0.22 mM], and 2% [0.44 mM]). Thus,
the degree of accuracy achieved for analysis of halothane
is less than that achieved for the caffeine data. Alter-
natively, these data may suggest a different mechanism
of action for halothane at lower concentrations than at
higher concentrations. Importantly, these data are ofma-
jor significance for the assessment of potential false-pos-
itive diagnoses of susceptibility to MH, in genetic stud-
ies, since they indicate the difficulty of differentiating
potential false-positive diagnoses on the basis of a hal-
othane response. However, the analysis suggests that ex-
amination of the caffeine IVCT response is likely to be
a more reliable approach to this difficult problem inMH
genetics.
The data presented in figure 2A suggest thatmutations
veering toward the left of the graph might produce a
milder MH phenotype than mutations veering toward
the right. Because of the wide variety of surgical and
anesthetic procedures and the fact that anesthesia is
aborted as rapidly as possible after the appearance of
any MH-like symptoms, differences in the severity of
clinical episodes of MH are difficult to score, assess, and
compare. However, it is interesting to note that, in the
graph in figure 2A, the Arg163Cys mutation is in the
most rightward position and is the only mutation as-
sociated with symptomatic CCD (Quane et al. 1993).
Thus, the RYR1 mutations producing the most sensitive
caffeine phenotypes with the highest tension values may
possibly predispose the individual to MH and CCD.
Analysis of the IVCT data of other RYR1 mutations
associated with CCD will be necessary, to test this hy-
pothesis. A small percentage of individuals with the
Arg614Cys mutation are now known to test as MHN
in the European IVCT (Deufel et al. 1995), indicating
that this mutation may be relatively mild. This mutation
is in the third most leftward position on the graph. Fur-
thermore, the Cys35Arg mutation is in one of the most
leftward positions on the graph. Two individuals ho-
mozygous for this mutation have been reported (Lynch
et al. 1997). Similarly, one individual homozygous for
the Arg614Cys mutation has been reported (Deufel et
al. 1995). In each of these cases, the homozygous in-
dividual has been clinically normal, indicating that these
mutations may be relatively mild.
The central region of the RYR1 protein is predicted
to be cytoplasmic and has been ascribedmany important
functions, including those associated with a phosphor-
ylation site at Serine2844 (Suko et al. 1993) and with
a calmodulin binding site (Chen et al. 1993; O’Driscoll
et al. 1996). Although it is relatively clear that RYR1
mutations that are causative of the MHS phenotype lead
to hypersensitive gating of the channel, by agonists, the
exact mechanism by which thesemutations and the other
608 Am. J. Hum. Genet. 62:599–609, 1998
reported RYR1 mutations cause such hypersensitive gat-
ing is unclear.
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